Details for New Drug Application (NDA): 019675
✉ Email this page to a colleague
The generic ingredient in ZANTAC is ranitidine hydrochloride. There are forty-three drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the ranitidine hydrochloride profile page.
Summary for 019675
Tradename: | ZANTAC |
Applicant: | Glaxo Grp Ltd |
Ingredient: | ranitidine hydrochloride |
Patents: | 0 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SYRUP;ORAL | Strength | EQ 15MG BASE/ML | ||||
Approval Date: | Dec 30, 1988 | TE: | RLD: | Yes |
Expired US Patents for NDA 019675
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Glaxo Grp Ltd | ZANTAC | ranitidine hydrochloride | SYRUP;ORAL | 019675-001 | Dec 30, 1988 | 4,128,658 | ⤷ Subscribe |
Glaxo Grp Ltd | ZANTAC | ranitidine hydrochloride | SYRUP;ORAL | 019675-001 | Dec 30, 1988 | 5,068,249*PED | ⤷ Subscribe |
Glaxo Grp Ltd | ZANTAC | ranitidine hydrochloride | SYRUP;ORAL | 019675-001 | Dec 30, 1988 | 4,585,790*PED | ⤷ Subscribe |
Glaxo Grp Ltd | ZANTAC | ranitidine hydrochloride | SYRUP;ORAL | 019675-001 | Dec 30, 1988 | 4,521,431*PED | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription